Giotrif

Giotrif (Afatinib) is an oral medication used to treat certain types of cancer. This targeted therapy is designed to inhibit specific proteins involved in cancer cell growth.

Giotrif is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It works by targeting and blocking the epidermal growth factor receptor (EGFR), which can help slow the growth and spread of cancer cells. Patients often wonder, 'What is Giotrif used for?' and the answer lies in its role in managing advanced NSCLC with EGFR mutations.

Common effects of Giotrif may include skin rash, diarrhea, and fatigue. Some users also report nausea and loss of appetite. These effects can vary in severity and duration, depending on individual responses to the medication.

Giotrif should be handled with care, following the guidelines provided by healthcare professionals. It is important to store the medication properly and to follow any specific instructions for administration. Patients should be aware of potential side effects and report any severe or persistent symptoms to their healthcare provider.

Giotrif may interact with certain medications, including those that are metabolized by the liver's cytochrome P450 enzymes. It is advisable to inform healthcare providers about all current medications to avoid potential interactions. Additionally, alcohol and other substances may affect the efficacy and safety of Giotrif.